Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor
cells.
PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with
hydroxyurea works in treating patients with recurrent or progressive meningioma.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals